Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Summary

Prenylation is an important modification on peripheral membrane binding proteins. Insect cells can be manipulated to produce farnesylated and carboxymethylated KRAS4b in quantities that enable biophysical measurements of protein-protein and protein-lipid interactions

Abstract

Protein prenylation is a key modification that is responsible for targeting proteins to intracellular membranes. KRAS4b, which is mutated in 22% of human cancers, is processed by farnesylation and carboxymethylation due to the presence of a 'CAAX' box motif at the C-terminus. An engineered baculovirus system was used to express farnesylated and carboxymethylated KRAS4b in insect cells and has been described previously. Here, we describe the detailed, practical purification and biochemical characterization of the protein. Specifically, affinity and ion exchange chromatography were used to purify the protein to homogeneity. Intact and native mass spectrometry was used to validate the correct modification of KRAS4b and to verify nucleotide binding. Finally, membrane association of farnesylated and carboxymethylated KRAS4b to liposomes was measured using surface plasmon resonance spectroscopy.

Introduction

Posttranslational modifications play a key role in defining the functional activity of proteins. Modifications such as phosphorylation and glycosylation are well established. Lipid modifications are less well characterized, however. It is estimated that as much as 0.5% of all cellular proteins may be prenylated¹. Prenylation is the transfer of a 15-carbon farnesyl or a 20-carbon geranylgeranyl lipid chain to an acceptor protein containing the CAAX motif². Prenylated proteins have been implicated in the progression of several human diseases including premature aging³, Alzheimer's⁴, cardiac dysfunction⁵, choroideremia⁶, and cancer⁷. The small GTPases, HRAS, NRAS, and KRAS¹, nuclear laminins, and the kinetochores CENP-E and F are farnesylated proteins under the basal condition. Other small GTPases, namely RhoA, RhoC, Rac1, cdc-42, and RRAS are geranylgeranylated⁸, whereas RhoB can be farnesylated or geranylgeranylated⁹.

The small GTPase KRAS4b functions as a molecular switch, essentially transmitting extracellular growth factor signaling to intracellular signal transduction pathways that stimulate cell growth and proliferation, via multiple protein-protein interactions. There are two key aspects of KRAS4b biochemistry that are essential for its activity. First, the protein cycles between an inactive GDP and an active GTP bound state whereby it actively engages with effectors. Second, a C-terminal poly-lysine region and a farnesylated and carboxymethylated cysteine direct the protein to the plasma membrane, enabling recruitment and activation of downstream effectors. Mutant KRAS4b is an oncogenic driver in pancreatic, colorectal, and lung cancer¹⁰, and as such, therapeutic intervention would have a huge clinical benefit. Production of authentically modified recombinant protein that is farnesylated and carboxymethylated would enable biochemical screening using KRAS4b in combination with membrane surrogates such as liposomes or lipid nanodiscs^11,12.

Farnesyl transferase (FNT) catalyzes the addition of farnesyl pyrophosphate to the C-terminal cysteine in the CAAX motif in KRAS4b. After prenylation, the protein is trafficked to the endoplasmic reticulum (ER) where the Ras converting enzyme (RCE1) cleaves the three C-terminal residues. The final step in processing is methylation of the new C-terminal farnesylcysteine residue by the ER membrane protein, isoprenylcysteine carboxyl methyltransferase (ICMT). Expression of recombinant KRAS4b in E. coli results in the production of an unmodified protein. Previous attempts to produce processed KRAS4b have been limited due to insufficient yields for structural or drug screening experiments or have failed to recapitulate the native full-length mature protein^13,14. The protocol presented here utilizes an engineered baculovirus-based insect cell expression system and purification method that generates highly purified, fully processed KRAS4b at yields of 5 mg/L of cell culture.

Careful protein characterization is essential to validate the quality of recombinant proteins prior to embarking on structural biology or drug screening studies. Two key parameters of fully processed KRAS4b are validation of the correct prenyl modification and the availability of the farnesylated and carboxymethylated C-terminus (FMe) for interaction with membrane substitutes or lipids. Electrospray ionization mass spectrometry (ESI-MS) of the KRAS4b-FMe was used to measure the molecular weight and confirm the presence of the farnesyl and carboxymethyl modifications. Native mass spectrometry, where samples are sprayed with nondenaturing solvents, was used to demonstrate that KRAS4b-FMe was also bound to its GDP cofactor. Finally, surface plasmon resonance spectroscopy was used to measure the direct binding of KRAS4b-FMe with immobilized liposomes.

Protocol

1. Protein purification

1. Prepare buffers A–H, as seen in Table 1.

Buffer solution	Buffering agent (all 20 mM)	pH	NaCl (mM)	imidazole (mM)	MgCl2	TCEP
A	HEPES	7.3	300	-	5	1
B	HEPES	7.3	300	35	5	1
C	HEPES	7.3	300	500	5	1
D	MES	6.0	200	-	5	1
E	MES	6.0	-	-	5	1
F	MES	6.0	100	-	5	1
G	MES	6.0	1000	-	5	1
H	HEPES	7.3	300	-	1	1

2. Prepare the purification materials (see Table of Materials): protease inhibitor cocktail without EDTA or other chelators; immobilized metal affinity chromatography (IMAC) column; cation exchange chromatography (CEX) column; 0.45 μm syringe filter; 2 M imidazole (pH = 7.5); ultracentrifuge capable of 100,000 x g; high speed benchtop centrifuge capable of 4,000 x g; centrifugal filter units (10 KDa NMWL); spectrophotometer capable of reading at 280 nm; His6-tobacco etch virus (TEV) protease; and chromatography instrumentation capable of mixing two buffer solutions, applying solutions to columns, creating gradient elutions from column, and collecting fractions from columns.
3. Thaw cells from ~2 L of insect cell culture previously stored at -80 °C or use freshly harvested cells. See Gillette et al. 2019¹⁵ for details about the Tni.FNL insect cell line and expression protocols. Carefully resuspend the cells with 200 mL of Buffer A with added 1:200 v/v protease inhibitor without introducing air or creating foam.
   NOTE: Step 1.3 and subsequent steps (except as noted) should be performed at room temperature (~22 °C). It is important that the sample be homogeneous to allow complete lysis in the next step.
4. Lyse cell pellet in a microfluidizer at 7,000 psi for two passes or in an equivalent lysis system. Alternative methods of lysis have not been explored.
5. Clarifying insect cell lysates is problematic due to the presence of compounds that clog filters. Thus, ultracentrifugation (100,000 x g for 30 min at 4 °C) is very important. A white lipid residue on the surface of the supernatant should be avoided and can be removed or reduced using cotton swabs. Filter the decanted supernatant through a 0.45 μm PES filter. Use the clarified sample immediately or store at -80 °C.
   NOTE: The residue blocks filters quickly and many filters may be necessary. Failure to reduce the amount of this material will lead to high column back pressure in subsequent steps.
6. Determine the volume of the clarified lysate and adjust the sample to 35 mM imidazole by the addition of 2 M imidazole stock. Load the sample at 3 mL/min onto a 20 mL IMAC column (HisPrep FF 16/10 column) pre-equilibrated in Buffer B for three column volumes (CVs).
7. Although the target protein is typically quantitatively adsorbed to the column, it is best to collect the column flow for subsequent analysis. Wash the column until the Abs₂₈₀ reaches a steady baseline (<100 milliabsorbance units [mAU]) with Buffer B at 3 mL/min for 20 mL (1 CV) then for ~3 CV at 4 mL/min for the remainder of the wash step. Typically, 60–80 mL of Buffer B is needed to achieve baseline absorbance.
8. Elute the protein with a 400 mL (20 CV) gradient from Buffer B to Buffer C while collecting 8 mL fractions. Typically, the target protein elutes in the first half of the gradient (Figure 1A; not all later fractions are shown).
9. Analyze protein fractions using SDS-PAGE/Coomassie staining. Pool peak fractions and dialyze the pool overnight against 2 L of Buffer D at 4 °C.
   NOTE: Low pH is critical to ensure protein binding in the next step. However, the pH change during this dialysis occurs slowly, and this is a convenient step for overnight incubation. Alternative buffer exchange strategies (e.g., higher buffer concentration to speed the pH change) have not been investigated. The protein will begin to slowly precipitate over time at lower pH and lower salt concentrations and a small amount of precipitation is normal during this step. Because of this, we avoid exchanging the buffer to the 100 mM NaCl necessary for binding to the next column during dialysis. Rather, an NaCl concentration of 200 mM is used for dialysis and the protein is diluted to 100 mM (see below) immediately prior to application to the column. We have not investigated if this precipitation is specific to KRAS4b, but the protein that does precipitate has been confirmed as KRAS4b-FMe. For this reason, we suggest using the higher NaCl concentration in the dialysis buffer for any protein of interest as a precaution until the stability of the target protein in the binding buffer can be determined.
10. Remove the sample from dialysis and centrifuge at 4,000 x g for 10 min to remove any precipitate. The final dialyzed, clarified sample at this point is still often hazy but can be applied without further processing onto the subsequent CEX column.
11. Prepare a 20 mL cation exchange column (see Table of Materials) by washing with three CVs of Buffer G, then with three CVs of Buffer F.
    NOTE: While we have not meticulously evaluated other resins, several colleagues have found poor resolution with resins other than SP Sepharose High Performance resin.
12. Dilute 20 mL of the dialyzed sample to a final NaCl concentration of 100 mM by adding 20 mL of Buffer E and apply the diluted sample to the cation exchange column.
13. Continue to load the column by adding freshly diluted samples prepared as described above to the load tube as the previous dilution is nearing the end of the load.
    NOTE: Diluting the entire sample at once to 100 mM NaCl has resulted in significant loss of target protein due to precipitation.
14. Wash the column to baseline Abs₂₈₀ with Buffer F. This typically requires 3 CV. The protein is eluted from the column during a 400 mL (20 CV) gradient from Buffer F to 65% Buffer G, collected in 6 mL fractions (Figure 1B).
15. Continue washing the column for an additional 1.5 CV (65% Buffer G) once the gradient is completed. Choose positive fractions based on both SDS-PAGE/Coomassie blue stain analysis and inspection of the UV trace of the chromatogram.
    NOTE: The UV trace typically contains five peaks. Beginning at lower salt concentrations, the initial peak is usually unprocessed and/or proteolyzed protein. The second and third peaks are a mixture of two forms of processed protein: the second peak is primarily a farnesylated intermediate (FARN), while the third is primarily the fully processed FMe protein of interest. Peaks four and five represent His6-MBP-KRAS4b fusion proteins (all of the protein is in this format at this point, as no TEV digestion has occurred). These are not N-acetylated at the N-terminus and are farnesylated (peak four) and farnesylated and carboxymethylated (peak five) at the C-terminus. As peak two and peak four will produce identical proteins after tag removal (i.e., KRAS4b-FARN) these can be pooled at this stage if desired. Similarly, peak three and peak five can be combined to produce a single lot of KRAS4b-FMe (Figure 1B, Figure 2). However, it is advised that this pooling only be done when the nature of the protein in the separate peaks has been confirmed.
16. Digest the protein pooled in step 1.15 with His6-TEV protease (~200 μg of protease/mL of sample.
    NOTE: We make His6-TEV protease using the plasmid and protocols available from Addgene (https://www.addgene.org/92414). Dialyze the TEV digest against Buffer A (10 kDa MWCO dialysis tubing with a minimum of 40 mL of Buffer A per mL of sample) for 2 h at room temperature and then overnight at 4 °C.
17. After digestion and dialysis, load the protein directly to a 20 mL IMAC column equilibrated with Buffer A at 3 mL/min.
    NOTE: Collect 7 mL fractions during this entire chromatography, because the target protein has a low affinity for the column but might not be entirely bound to the resin. Wash the column at 3 mL/min with Buffer A for a total of 3 CVs or until a baseline absorbance is reached.
18. The target protein is eluted with a 5 CV gradient of Buffer C from 0%–10%, collecting 7 mL fractions. As a precaution, additional bound proteins can be eluted with 100% Buffer C. Positive fractions are identified after analysis by SDS-PAGE (Figure 1C). Typically, the target protein elutes at a low imidazole concentration (i.e., in the 0%–10% Buffer C gradient) but sometimes elutes in the flow-through or column wash.
19. Dialyze the final pool against Buffer H. Determine the protein concentration by spectrophotometry at 280 nm.
    NOTE: Be sure to account for the presence of the nucleotide when determining the extinction coefficient to use for this calculation.
20. The protein can be concentrated to ~2–5 mg/mL using a centrifugal filter unit (10 K NMWL) without significant protein loss. Filter with a 0.22 μM syringe filter. Measure the solution absorbance at A₂₈₀ to calculate the final protein concentration (Figure 1D). Snap freeze aliquots in liquid nitrogen and store frozen samples at -80 °C.
    NOTE: The protein purified is bound to GDP. KRAS4b-FMe can be exchanged into GppNHp using previously published protocols¹⁶.

2. Sample preparation for intact mass analysis and native mass analysis

1. Sample preparation for intact mass analysis
   1. Thaw protein sample on ice prior to analysis. For intact mass analysis, dilute the protein to 0.1 mg/mL in 20 mM ammonium bicarbonate (pH = ~8.4). For native mass analysis, dilute the protein to a concentration of 0.1 mg/mL in 50 mM ammonium acetate (pH = ~7.5). Vortex each sample for 5–10 s, then centrifuge at 12,500 x g for 1 min to pellet any solid material in the solution. Remove 10–20 µL of each supernatant and transfer to a glass autosampler vial. Cap each vial tightly to prevent contamination or evaporation.
      NOTE: For either intact mass analysis or native mass analysis, the sample may be desalted prior to analysis using a 10 kDa MWCO cellulose membrane filter to buffer-exchange into the final dilution buffer.
2. Preparation of the extended mass range (EMR) mass spectroscopy for mass analysis
   NOTE: Prior to running any analysis on the mass spectrometer, make sure that it has been recently calibrated. Also, always wear gloves and other personal protective equipment as necessary to avoid any harmful chemicals and to avoid contaminating samples and solvents. Calibration is done using a calibration solution obtained commercially and a 2 mg/mL cesium iodide solution prepared in-house.
   1. Open the analysis software and load the appropriate instrument method file. For intact mass analysis of KRAS4b proteins, suitable starting parameters are as follows: positive mode of detection; three microscans, resolution = 70,000; AGC target = 3e⁶; maximum integration time = 200 ms; and a scan range = 70–1,800 mass-to-charge ratio (m/z). For native mass analysis of KRAS4b proteins, suitable starting parameters are as follows: positive mode of detection; 10 microscans, resolution = 17,500; in-source collision-induced dissociation (CID) = 20 eV; AGC target = 3e⁶; collision energy (CE) = 20; maximum integration time = 200 ms; and a scan range = 500–10,000 m/z.
3. Preparation of chromatographic solvents and column
   1. Prepare the solvents necessary for intact mass analysis. Solvent A is water with 0.1% formic acid. Solvent B is 80% acetonitrile and 0.1% formic acid in water.
   2. Prepare the solvents necessary for native mass analysis. Solvent A is 0.1 M ammonium acetate in water and Solvent B is water.
   3. After the appropriate solvents are prepared, purge the system so that the tubing is filled with the appropriate solvents and all air bubbles are removed from the lines.
   4. Install the appropriate column (a reverse-phase column for intact mass analysis and a size exclusion column for native mass analysis). For intact mass analysis, the flow rate is 0.5 mL/min, and the column temperature (using a column heater) is 50 °C. Equilibrate the column for 15–20 min. For native mass analysis, the flow rate is 0.25 mL/min.
      NOTE: Always monitor the column back-pressure to ensure that it does not rise above the upper limit, which could indicate a clogged line or that the column matrix is compromised. Replace the column if necessary.
4. Sample analysis
   1. Place the prepared protein sample in the glass autosampler vial into the appropriate vial rack in the LC systems autosampler. Create a sample(s) list in the software program with the appropriate instrument method for the desired analysis. Once the sample list is complete, click the Play button to start the analysis.
   2. Inject 1–2 μL of sample per analysis, with a water blank before and after each sample, to ensure no carry-over is present.
      NOTE: The intact mass analysis is very different than the native mass analysis and requires very different instrument method settings. This is because with the intact mass analysis, the protein is "relaxed" in the presence of an organic solvent, and thus is capable of accepting more charges. It is easier to deconvolute and resolve the isotopic distribution of the charge states. Native mass analysis provides a narrow charge distribution of the protein ions, and based on the protein, requires different voltage and collision energy settings.
5. Data analysis and protein deconvolution
   1. Export the spectrum of the sample to software where it can be transformed to the de-convoluted spectrum that will display the intact mass (or native mass) of the protein. The intact mass will have an isotopic peak distribution due to the high abundance of charged spectral peaks. The native mass will typically have very few peaks due to the low abundance of the charged spectral peaks (Figure 3D).
   2. Expand the mass-to-charge ratio (m/z) range of the peak d to confirm that the measured mass is consistent with the predicted mass. Occasionally, due to the addition of charges to the protein, there may be a slight variation between the expected molecular weight (MW) and the observed MW. Also, as with many mass spectrometry analyses, adducts such as sodium can contribute to the appearance of additional peaks in the data, even with carefully desalted samples. Lower abundant peaks with an m/z that is lower than expected are sometimes observed. This is most likely due to a neutral loss, which is the loss of a functional group due to the ionization process.
      NOTE: As expected, there will be differences between the intact mass and the native mass peaks. The intact mass display will show the protein's expected MW. It will not have the extra MW of the attached nucleotide or other modifications. However, the native mass peak will show the protein with any added nucleotide.

3. Validation of KRAS4b-FMe binding to liposomes

1. Membrane liposomes preparation
   1. Prepare a buffer consisting of 20 mM HEPES (pH = 7.3), 150 mM NaCl, and 1 mM TCEP.
   2. Liposome preparation materials include 25 mM 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine (POPC) and 10 mM 1-palmitoyl-2-oleoyl-glycero-3-phospho-L-serine (POPS) stocks in chloroform; a lipid extruder set with a holder and heating block; argon gas and liquid nitrogen; an ultrasonic bath; glass screw thread vials with PTFE foam liners; and a plate reader capable of dynamic light scattering detection.
   3. Thaw lipid stocks in chloroform at room temperature for 30 min. Prepare 1 mL of 5 mM 70:30 POPC: POPS liposomes by aliquoting 106 μL of 25 mM POPC (stock) and 118 μL of 10 mM POPS (stock) into a glass vial.
      NOTE: Do not aliquot lipids with a plastic tip, because the chloroform could dissolve certain plastic tips.
   4. Dry lipids under a steady stream of argon gas. Slowly rotate the glass vial when applying the argon gas to form a thin layer of dry film.
   5. Put samples under a vacuum lyophilizer overnight to remove excess chloroform.
   6. Reconstitute the lipids by adding 1 mL of buffer to the dried film and vortex the mixtures for 5 min. Hydrate the lipid mixtures by rocking for 1 h at 25 °C.
      NOTE: The sample will be very turbid upon addition of the buffer to the dried film layer of lipids.
   7. Perform five freeze/thaw cycles by alternating placing the sample vial between an ice-water (4 °C or lower) and a warm water bath (25 °C or higher).
   8. Place the sample vial into the ultrasonic bath and sonicate the sample for about 0.5 h or until the sample becomes semitransparent.
   9. Extrude the samples using the lipid extruder set. Assemble the extrusion kit as shown in the manufacturer's instructions. Extrude the samples using 0.1 μm filter paper. Load the samples into one glass syringe and attach it to one end of the extrusion apparatus. Add an empty syringe on the other end of the extrusion apparatus. Push back and forth 10–20x until your samples become fully transparent.
   10. Spin the final samples for 30 min at 20,000 x g to remove any large aggregates.
   11. Use dynamic light scattering (DLS) to determine the size and homogeneity of the liposomes (optional). Place 30 μL of the liposomes into a 384 well plate reader. Spin the plate at 1,000 x g for 30 min. Place the plate into a plate reader and collect 10 light scattering measurements.
2. Charactering KRAS4b-FMe binding to liposomes via surface plasmon resonance (SPR)
   1. Assemble the required materials: an SPR instrument; sensor chip L1; 7 x 14 mm vial tubes; and CHAPS.
   2. Prepare a buffer containing 20 mM HEPES (pH = 7.3), 150 mM NaCl, 1 mM TCEP. Prepare a 2:1 dilution series of KRAS4b-FMe from 60 μM–0.06 μM in a total volume of 200 μL (10 titrations total). Transfer the final diluted samples into vial tubes (see Table of Materials), place the vial tubes into a rack, and insert the samples into the SPR instrument.
   3. Insert the L1 sensor chip into the SPR instrument. Attach the buffer and prime the system with buffer for 7 min.
   4. Set up an automated method as follows:
      1. Set the instrument temperature to 25 °C.
      2. Activate the sensor chip L1 by rinsing it with two 1 min injections of 20 mM CHAPS dissolved in water at 30 μL/min flow rate.
      3. Perform start-up cycles of ten 1 min injections of running buffer to hydrate the chip surface.
         1. Deposit the liposomes onto the sensor chip L1 by injecting the liposomes onto the flow cell (FC)-2 of the L1 chip with 2 min injections at 5 μL/min. Aim for a capture level of at least ~3,000 response units (RUs).
            NOTE: Increase the injection time until you achieve the appropriate capture level.
      4. Inject three cycles of buffer over both FC-1 and FC-2 with 1 min injections at 30 μL/min.
         1. Inject the various KRAS4b-FMe titrations from the lowest to the highest concentration series. Inject the proteins using 1 min injections for the association phase and 2 min injections for the dissociation phase at 30 μL/min flow rate over both FCs.
         2. Regenerate the sensor chip L1 by rinsing it with two 1 min injections of 20 mM CHAPS at 30 μL/min.
   5. Fit the data using the SPR evaluation software using a single site binding model to obtain apparent binding affinities (see the Discussion section for an explanation of data fitting).

Results

One of the largest variables in the protocol is the amount of expressed target protein (His6-MBP-tev-KRAS4b). This protocol was developed using an isolate from a Trichoplusia ni cell line, Tni-FNL¹⁷, adapted for suspension growth and weaned from serum. Given the wide range of results reported across the various insect cell lines with the baculovirus expression system, it is advisable that Tni-FNL be used, at least initially, to produced KRAS4b-FMe.

A dark prote...

Discussion

As noted in the Representative Results section, the most critical step during the purification is the handling of the sample during the time it is in lower salt. Limiting the time that the sample is exposed to less than 200 mM NaCl will help reduce precipitation and increase sample yield. Interpretation of the results of the CEX can be difficult if the profile does not match the expectations (see Figure 2). Until the protocol has become routine, it is advised that the CEX elution fractions t...

Materials

Name	Company	Catalog Number	Comments
1.8 mL Safe-Lock Tubes, Natural	Eppendorf	22363204
11 mm Cl SS Interlocked Insert Autosampler Vials	Thermo Scientific	30211SS-1232
1-palmitoyl-2-oleoyl-glycero-3-phosphocholine (POPC)	AVANTI POLAR LIPIDS	850457	purchase as liquid stocks in chloroform
1-palmitoyl-2-oleoyl-glycero-3-phospho-L-serine (POPS)	AVANTI POLAR LIPIDS	840034	purchase as liquid stocks in chloroform
5427R Centrifuge	Eppendorf
Acetonitrile, HPLC Grade	Fisher Chemical	A998-1 1L
Ammonium Acetate	Sigma-Aldrich	09689-250g
Argon gas	Airgas	ARUP
Assay Plate 384	CORNING	3544
Biacore T200 Instrument	GE Healthcare
Blue Snap-It Seals, T/S	Thermo Scientific	C4011-54B
Branson Ultrasonic Bath	Thermo Fisher	15-336-1000
Cation Exchange Chromatography (CEX) column	GE Healthcare Life Sciences	29018183	HiPrep SP Sepharose High Performance
CHAPS	Sigma	C3023
Dyna Pro Plate Reader	Wyatt Technologies
Exactive Plus EMR Mass Spectrometer	Thermo Scientific
Formic Acid	Sigma-Aldrich	F0507-500Ml	Use Reagent Grade or better
Gilson vials 7x14 mm Tubes	GE Healthcare	BR-1002-12
Glass screw thread vials with PTFE foam liners	Scientific Specialities	B69302
High speed/benchtop centrifuge	Thermo Fischer Scientific	05-112-114D	capable of up to 4,000 xg
His6-Tobacco Etch Virus (TEV) protease	Addgene	92414	Purified as per Raran-Kurussi et al. (2017) Removal of Affinity Tags with TEV Protease. In: Burgess-Brown N. (eds) Heterologous Gene Expression in E.coli. Methods in Molecular Biology, vol 1586. Humana Press, New York, NY
Immobilized Metal Affinity Chromatography (IMAC) column	GE Healthcare Life Sciences	28-9365-51	HisPrep FF 16/10
In-House Water Supply, Arium Advance	Sartorius Stedim		Resistivity of 18 MΩ0-cm
Lipid extruder set with holder	AVANTI POLAR LIPIDS	610023
Liquid nitrogen	Airgas	NI-DEWAR
M110-EH microfluidizer	Microfluidics
MabPac RP UHPLC Column, 4 um, 3.0 x 50 mm	Thermo Scientific	088645
MabPac SEC-1 Column, 5 um, 300 Å, 2.1 x 150 mm	Thermo Scientific	088790
MagTran software	Thermo Scientific
Methanol, HPLC Grade	VWR Chemicals	BDH20864.400
NGC Chromatography System	BioRad	78880002	NGC QuestTM 100 Chromatography system
Protease Inhibitor Cocktail without EDTA or other chelators	Millipore Sigma	P8849
Rubber Caps type 3	GE Healthcare	BR-1005-02
Series S Sensor Chip L1	GE Healthcare	29104993
Spectrophotometer	Thermo Fischer Scientific	13-400-519	Absorbace at 280nm
Ultra-15 Centrifugal Filter Units, 10K NMWL	Millipore Sigma	UFC901008	PES membrane
Ultracel 10K MWCO Ultra 0.5 mL Centrifuge Filters	Amicon	UFC501024
Ultracentrifuge	Beckman Coulter	Optima - L80K	capable of 100,000 xg
Vanquish UHPLC (Pump, Column Hearter, and LC System)	Thermo Scientific
Vortex Genie 2	Fisher	12-812
Water, HPLC Grade	Sigma-Aldrich	270733-1L	May use in-house water source (see below)
Whatman GD/XP PES 0.45 mm syringe filter	GE Healthcare - Whatman	6994-2504
Xcalibur QualBrowser	Thermo Scientific		proteomics software